HU176046B - Process for producing 2,6-disubstituted-9-/beta-d-arabinofuranozil/-5'-phosphates, their pharmaceutically accepta ble salts and pharmaceutical composition containing them - Google Patents
Process for producing 2,6-disubstituted-9-/beta-d-arabinofuranozil/-5'-phosphates, their pharmaceutically accepta ble salts and pharmaceutical composition containing them Download PDFInfo
- Publication number
- HU176046B HU176046B HU76WE537A HUWE000537A HU176046B HU 176046 B HU176046 B HU 176046B HU 76WE537 A HU76WE537 A HU 76WE537A HU WE000537 A HUWE000537 A HU WE000537A HU 176046 B HU176046 B HU 176046B
- Authority
- HU
- Hungary
- Prior art keywords
- phosphate
- arabinofuranosyl
- purine
- disubstituted
- formula
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 11
- 150000003839 salts Chemical class 0.000 title abstract description 10
- 239000010452 phosphate Substances 0.000 claims abstract description 37
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 7
- 239000002777 nucleoside Substances 0.000 claims description 16
- 239000011574 phosphorus Substances 0.000 claims description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims description 16
- -1 phosphate compound Chemical class 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001805 pentosyl group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- AFINAILKDBCXMX-PBHICJAKSA-N (2s,3r)-2-amino-3-hydroxy-n-(4-octylphenyl)butanamide Chemical compound CCCCCCCCC1=CC=C(NC(=O)[C@@H](N)[C@@H](C)O)C=C1 AFINAILKDBCXMX-PBHICJAKSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 38
- 125000003729 nucleotide group Chemical group 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 10
- 238000009472 formulation Methods 0.000 abstract description 5
- 230000009385 viral infection Effects 0.000 abstract description 3
- 208000036142 Viral infection Diseases 0.000 abstract description 2
- 150000003212 purines Chemical class 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 11
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
- 125000003835 nucleoside group Chemical group 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000002211 ultraviolet spectrum Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102000004357 Transferases Human genes 0.000 description 5
- 108090000992 Transferases Proteins 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 241000450599 DNA viruses Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 241000607715 Serratia marcescens Species 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 102000004008 5'-Nucleotidase Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010087227 IMP Dehydrogenase Proteins 0.000 description 2
- 102000006674 IMP dehydrogenase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- BJTZVFSJQBMTLN-UUBZBTQISA-N (2R,3S,4S)-2-(hydroxymethyl)-5-purin-3-yloxolane-3,4-diol Chemical compound C1([C@@H](O)[C@H](O)[C@H](O1)CO)N1C=NC=C2N=CN=C12 BJTZVFSJQBMTLN-UUBZBTQISA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- CFJZQNZZGQDONE-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;butanedioic acid Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)CCC(O)=O CFJZQNZZGQDONE-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- FCZOVUJWOBSMSS-UHFFFAOYSA-N 5-[(6-aminopurin-9-yl)methyl]-5-methyl-3-methylideneoxolan-2-one Chemical compound C1=NC2=C(N)N=CN=C2N1CC1(C)CC(=C)C(=O)O1 FCZOVUJWOBSMSS-UHFFFAOYSA-N 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 108010058222 Deoxyguanosine kinase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 206010019972 Herpes viral infections Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- GRSZFWQUAKGDAV-UHTZMRCNSA-N [(2r,3s,4s,5r)-3,4-dihydroxy-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHTZMRCNSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 229940067597 azelate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002862 dinucleoside phosphate Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Natural products NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- RSSHUWHSFGCSHG-UHFFFAOYSA-N tris(hydroxymethyl)azanium;chloride Chemical compound Cl.OCN(CO)CO RSSHUWHSFGCSHG-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Artificial Filaments (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB25768/75A GB1562899A (en) | 1975-06-17 | 1975-06-17 | Pharmaceutical compositions containing substituted 9-( -d-arabnofuranosyl)purine-5'-phosphate and salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU176046B true HU176046B (en) | 1980-11-28 |
Family
ID=10232986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU76WE537A HU176046B (en) | 1975-06-17 | 1976-06-17 | Process for producing 2,6-disubstituted-9-/beta-d-arabinofuranozil/-5'-phosphates, their pharmaceutically accepta ble salts and pharmaceutical composition containing them |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4136175A (forum.php) |
| JP (1) | JPS52295A (forum.php) |
| AU (1) | AU507515B2 (forum.php) |
| BE (1) | BE843082A (forum.php) |
| CA (1) | CA1052309A (forum.php) |
| CH (1) | CH632771A5 (forum.php) |
| CS (2) | CS192000B2 (forum.php) |
| DE (1) | DE2627156A1 (forum.php) |
| DK (1) | DK139727B (forum.php) |
| FI (1) | FI61315C (forum.php) |
| FR (1) | FR2361901A1 (forum.php) |
| GB (1) | GB1562899A (forum.php) |
| HU (1) | HU176046B (forum.php) |
| IL (1) | IL49822A (forum.php) |
| NL (1) | NL7606576A (forum.php) |
| SE (1) | SE429656B (forum.php) |
| ZA (1) | ZA763611B (forum.php) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58763B2 (ja) * | 1978-07-18 | 1983-01-07 | 三井造船株式会社 | 浮き防氷堤 |
| EP0015584A3 (de) * | 1979-03-12 | 1980-12-10 | Kailash Kumar Dr. Prof. Gauri | Neue Nukleotide, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4315000A (en) | 1980-07-07 | 1982-02-09 | Warner-Lambert Company | β-D-Arabinofuranosylimidazo(4,5-c)pyridine compounds and methods for their production |
| US4352795A (en) | 1981-01-29 | 1982-10-05 | Warner-Lambert Company | 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production |
| US4357324A (en) * | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| FR2518882A1 (fr) * | 1981-12-30 | 1983-07-01 | Pos Lab | Composition therapeutique, a base de monophosphate d'inosine, pour le traitement des troubles d'accommodation de l'oeil |
| US4594415A (en) * | 1982-03-29 | 1986-06-10 | Robins Roland K | Azole dinucleotide compositions and methods of use |
| DE3784655T2 (de) * | 1986-12-18 | 1993-07-15 | Kyowa Hakko Kogyo Kk | Verfahren zur herstellung von ascorbinsaeure-2-phosphat. |
| JPH0678352B2 (ja) * | 1990-06-27 | 1994-10-05 | アシュ スチーブンス，インコーポレイテッド | ９―ベータ―ｄ―アラビノフラノシル―２―フルオロアデニン ５’―ホスフェートの製造法 |
| US5866429A (en) * | 1991-04-03 | 1999-02-02 | Bloch; Will | Precision and accuracy of anion-exchange separation of nucleic acids |
| US6319908B1 (en) * | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| US6872710B2 (en) * | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| TW593331B (en) * | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| US7678836B2 (en) * | 1999-11-04 | 2010-03-16 | Fxs Ventures, Llc | Method for rendering a contact lens wettable |
| US8557868B2 (en) * | 2000-11-04 | 2013-10-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions using low molecular weight amines |
| US20070110782A1 (en) * | 2000-11-08 | 2007-05-17 | Fxs Ventures, Llc | L-histidine in ophthalmic solutions |
| US9492582B2 (en) * | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| US20070098813A1 (en) * | 2000-11-08 | 2007-05-03 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions with a peroxide source and a preservative |
| US9308264B2 (en) | 2000-11-08 | 2016-04-12 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
| US20060148665A1 (en) * | 2000-11-08 | 2006-07-06 | Bioconcept Laboratories | Ophthalmic and contact lens solutions containing forms of vitamin b |
| US20070104744A1 (en) * | 2000-11-08 | 2007-05-10 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing forms of vitamin b |
| CA2434961C (en) * | 2000-11-08 | 2010-05-25 | Bio-Concept Laboratories | L-histidine in ophthalmic solutions |
| US20060142169A1 (en) | 2000-11-08 | 2006-06-29 | Bioconcept Laboratories | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| US6624203B1 (en) * | 2001-11-08 | 2003-09-23 | Francis X. Smith | Nucleic acid bases used in ophthalmic solutions |
| AU2003261354A1 (en) * | 2002-08-02 | 2004-02-23 | The Regents Of The University Of California | New uses for inhibitors of inosine monophosphate dehydrogenase |
| US7939501B2 (en) * | 2003-04-15 | 2011-05-10 | Smith Francis X | Ophthalmic and contact lens solutions containing peptides as preservative |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3328389A (en) * | 1964-08-07 | 1967-06-27 | Sankyo Co | Process for preparing nucleotide derivatives |
| US3300478A (en) * | 1965-06-01 | 1967-01-24 | Upjohn Co | Arabinofuranosyl 2', 5'-and 3'-5'-dinucleoside phosphates and process therefor |
| US3382232A (en) * | 1965-08-26 | 1968-05-07 | Takeda Chemical Industries Ltd | Method for the production of 5'-ribonucleotide |
| US3337530A (en) * | 1965-09-20 | 1967-08-22 | Upjohn Co | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety |
| US3448098A (en) * | 1966-09-27 | 1969-06-03 | Merck & Co Inc | Production of guanylic acid |
| BE756704A (fr) * | 1969-09-26 | 1971-03-01 | Parke Davis & Co | Procede de production du 5'-phosphate de 9-(beta-d- arabinofuranosyl) adenine et de ses sels |
| BE759011A (fr) * | 1969-11-17 | 1971-05-17 | Wellcome Found | Aminopurines |
| GB1386585A (en) * | 1970-11-16 | 1975-03-12 | Wellcome Found | Purine sugar derivatives |
| GB1386584A (en) * | 1970-11-16 | 1975-03-12 | Wellcome Found | Method of preparation of purine sugar derivatives |
| DE2413226A1 (de) * | 1973-03-19 | 1974-10-24 | Icn Pharmaceuticals | 9-beta-d-arabinofuranosyl-nukleotide |
-
1975
- 1975-06-17 GB GB25768/75A patent/GB1562899A/en not_active Expired
-
1976
- 1976-06-16 US US05/696,519 patent/US4136175A/en not_active Expired - Lifetime
- 1976-06-16 DE DE19762627156 patent/DE2627156A1/de not_active Withdrawn
- 1976-06-17 DK DK271876AA patent/DK139727B/da not_active IP Right Cessation
- 1976-06-17 BE BE168038A patent/BE843082A/xx not_active IP Right Cessation
- 1976-06-17 SE SE7606913A patent/SE429656B/xx not_active IP Right Cessation
- 1976-06-17 CH CH776276A patent/CH632771A5/de not_active IP Right Cessation
- 1976-06-17 ZA ZA00763611A patent/ZA763611B/xx unknown
- 1976-06-17 NL NL7606576A patent/NL7606576A/xx not_active Application Discontinuation
- 1976-06-17 FI FI761759A patent/FI61315C/fi not_active IP Right Cessation
- 1976-06-17 CS CS777259A patent/CS192000B2/cs unknown
- 1976-06-17 IL IL49822A patent/IL49822A/xx unknown
- 1976-06-17 CA CA255,102A patent/CA1052309A/en not_active Expired
- 1976-06-17 JP JP51071647A patent/JPS52295A/ja active Pending
- 1976-06-17 HU HU76WE537A patent/HU176046B/hu unknown
- 1976-06-17 FR FR7618390A patent/FR2361901A1/fr active Granted
- 1976-06-17 AU AU15004/76A patent/AU507515B2/en not_active Expired
- 1976-06-17 CS CS764004A patent/CS191976B2/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI61315C (fi) | 1982-07-12 |
| SE7606913L (sv) | 1976-12-18 |
| CS191976B2 (en) | 1979-07-31 |
| FI761759A7 (forum.php) | 1976-12-18 |
| FI61315B (fi) | 1982-03-31 |
| SE429656B (sv) | 1983-09-19 |
| CS192000B2 (en) | 1979-07-31 |
| CA1052309A (en) | 1979-04-10 |
| DK271876A (forum.php) | 1976-12-18 |
| GB1562899A (en) | 1980-03-19 |
| IL49822A (en) | 1979-11-30 |
| CH632771A5 (de) | 1982-10-29 |
| DK139727B (da) | 1979-04-02 |
| DE2627156A1 (de) | 1977-01-13 |
| ZA763611B (en) | 1978-01-25 |
| US4136175A (en) | 1979-01-23 |
| BE843082A (fr) | 1976-12-17 |
| NL7606576A (nl) | 1976-12-21 |
| DK139727C (forum.php) | 1979-09-17 |
| FR2361901B1 (forum.php) | 1978-12-15 |
| JPS52295A (en) | 1977-01-05 |
| AU507515B2 (en) | 1980-02-21 |
| FR2361901A1 (fr) | 1978-03-17 |
| AU1500476A (en) | 1977-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU176046B (en) | Process for producing 2,6-disubstituted-9-/beta-d-arabinofuranozil/-5'-phosphates, their pharmaceutically accepta ble salts and pharmaceutical composition containing them | |
| EP1589026B1 (en) | 4'-C-Substituted-2-Haloadenosine derivative | |
| AU747196B2 (en) | Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof | |
| CA1322748C (en) | Adenosine deaminase-stable anti-retroviral nucleosides | |
| RU2043361C1 (ru) | Способ получения производных 2'-дезокси-2'-фторрибонуклеозидов или их фармацевтически приемлемых солей | |
| US4963662A (en) | Fluorinated nucleosides and method for treating retrovirus infections therewith | |
| US5106837A (en) | Adenosine derivatives with therapeutic activity | |
| US4826823A (en) | Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts | |
| US4430495A (en) | Process for preparing lincomycin and clindamycin ribonucleotides | |
| US5661136A (en) | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents | |
| US4210638A (en) | Antiviral composition and method of treating virus diseases | |
| AU626296B2 (en) | Substituted adenine derivatives useful as therapeutic agents | |
| US3337530A (en) | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety | |
| US4719295A (en) | Compound 2-iodo-2'-deoxyadenosine | |
| WO1999043690A1 (fr) | Compose de l-4'-arabinofuranonucleoside et composition medicinale le contenant | |
| WO1996001834A1 (fr) | 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside | |
| US5153180A (en) | Fluorinated nucleosides and process for treating retrovirus infections therewith | |
| US3317512A (en) | 5', 5'-dinucleoside phosphates | |
| US4481197A (en) | Anti-inflammatory deoxyribosides | |
| US4874751A (en) | Antibacterial treatment | |
| US4908441A (en) | Deoxyadenosine compounds and methods of making and using the same | |
| US7939510B2 (en) | Di(uridine 5′-)tetraphosphate and salts thereof | |
| US4297347A (en) | Nucleoside derivatives and an antileukemial agent containing the same as an active ingredient | |
| DK149958B (da) | Analogifremgangsmaade til fremstilling af 4-amino-1-(2-desoxy-beta-d-ribofuranosyl)-1h-imidazo-(4,5-c)pyridin eller estere eller salte deraf | |
| JPS6270387A (ja) | ４−アミノ−３−ハロ−２−ピリジノンヌクレオシドおよびヌクレオチド化合物 |